Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tagrisso Climbs Close To Top Of AstraZeneca Sales Tree

Executive Summary

The drug major has presented a set of financials that have comfortably surpassed analyst forecasts and show that its new oncology therapies now make up around 30% of group sales and are growing strongly.

You may also be interested in...



Q1 Drug Sales, Pipeline, 2019 Catalysts Top Themes For AstraZeneca Update

Q1 Earnings Preview: When AstraZeneca reports first-quarter results on April 26 investor focus will be on new product sales growth, pipeline catalysts and clues on possible fresh divestment and licensing deals.

AZ China Growth Pops Again But Clouds Loom

Lying underneath AstraZeneca’s stellar quarter were the growth engines of emerging markets and China, where novel drugs, especially in oncology, delivered. But mounting pricing pressures and a massive new centralized bidding process are clouds on the horizon.

Farewell To MedImmune: AstraZeneca Will Combine Large And Small Molecule Research

The company will integrate MedImmune, which has operated as the biologics research arm of AstraZeneca, amid an R&D and commercial restructuring.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC124674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel